Michael Richman
michaelrichman
profile
"Amplimmune develops novel, proprietary biologics that re-balance the human immune system… an important charter that requires dependable funding. By working with InterWest, we’re working with Life Science experts who also have a clear understanding of the entrepreneurial environment. They understand fundraising cycles and provide invaluable guidance to young companies through their most challenging times.”"
website
www.amplimmune.comLeadership
Michael Richman, President and CEODescription
Amplimmune develops immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Its founders have identified key immunomodulatory molecules which are the basis for developing a new class of biological treatments that modulate critical mechanisms in the body's immune system with the aim of bettering the lives of patients. Amplimmune was acquired by Astrazeneca (AZN) in 2013.
